NeuroSense to Host Investor Webinar on December 8, 2025

Rhea-AI Summary

NeuroSense (NASDAQ: NRSN) will host an investor webinar on December 8, 2025 at 8:30 a.m. ET to provide business, regulatory and clinical updates.

Planned topics include the Phase 3 PARAGON study initiation (ALS), submission for Notice of Compliance with conditions (NOC/c) in Canada, the status of a binding term sheet executed in December 2024, and updates on the RoAD Phase 2 program (Alzheimer's disease). Investors can register to attend the webcast.

Business, regulatory and clinical updates will be provided

CAMBRIDGE, Mass., Nov. 3, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that it will host an investor update meeting on December 8, 2025 at 8:30 a.m. Eastern Time.

The Company plans to provide status updates about its near-term milestones and objectives:

1. Phase 3 PARAGON study initiation (ALS)
2. Notice of Compliance with conditions (NOC/c) submission in Canada
3. Status of the binding term sheet executed in December 2024
4. RoAD Phase 2 program (Alzheimer's disease)

Investors interested in attending the webinar are invited to register here.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; timing for reporting data; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/neurosense-to-host-investor-webinar-on-december-8-2025-302602495.html

SOURCE NeuroSense

FAQ

When is NeuroSense (NRSN) hosting the investor webinar and how can I attend?

The webinar is scheduled for December 8, 2025 at 8:30 a.m. ET; investors can register via the company's investor registration link.

Will NeuroSense (NRSN) discuss the Phase 3 PARAGON study (ALS) on December 8, 2025?

Yes; the company plans to provide a status update on the Phase 3 PARAGON study initiation for ALS during the webinar.

Will NeuroSense (NRSN) provide details about its NOC/c submission in Canada at the webinar?

Yes; the webinar will include an update on the Notice of Compliance with conditions (NOC/c) submission in Canada.

Will NeuroSense (NRSN) update investors on the December 2024 binding term sheet at the webcast?

Yes; the company intends to discuss the status of the binding term sheet executed in December 2024.

Will NeuroSense (NRSN) discuss the RoAD Phase 2 program (Alzheimer's) in the investor meeting?

Yes; the agenda includes an update on the RoAD Phase 2 program for Alzheimer's disease.